TC Biopharm (Holdings) Plc (TCBPY)
OTCMKTS · Delayed Price · Currency is USD
0.3075
-0.0245 (-7.38%)
Sep 2, 2025, 1:01 PM EDT

TC Biopharm (Holdings) Company Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States.

Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers.

The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TC Biopharm (Holdings) Plc
CountryUnited Kingdom
Founded2013
IndustryBiotechnology
SectorHealthcare
Employees39
CEOBryan Kobel

Contact Details

Address:
Maxim 1
Motherwell, ML1 4WR
United Kingdom
Phone44 14 1433 7557
Websitetcbiopharm.com

Stock Details

Ticker SymbolTCBPY
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyGBP
SIC Code2836

Key Executives

NamePosition
Bryan Leland KobelChief Executive Officer and Director
Martin Edward ThorpChief Financial Officer and Director
Christopher CamarraExecutive Vice President of Communications
Dr. Lauren Bor Ph.D.Head of Commercial Development Division